BioCentury This Week

BioCentury Podcasts
  • 0.0 (0)
  • CIENCIAS DE LA VIDA
  • CADA SEMANA

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

  1. Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

    HACE 3 DÍAS

    Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

    RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, modalities, and precision medicines define cardiovascular disease catalysts this year. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the most important milestones of the year in new modalities, CV and renal diseases. The analysts also discuss a new regulation in China introducing orphan drug exclusivity that could incentivize development of rare disease therapies. Dig into the BioCentury’s catalyst picks and the new China policy below • 2026 Catalysts: The rise of RNAi • 2026 Cardiovascular Catalysts: Lp(a) on the Horizon • 2026 Obesity Catalysts: Launches, readouts and challengers • 2026 Catalysts: Breakthrough progress in renal disease • AZ signals all-in on obesity via CSPC deal for $1.2B up front • China’s orphan drug exclusivity could bolster market, incentivize development View full story: https://www.biocentury.com/article/658286 00:00 - Introduction 02:28 - RNAi and Antisense Therapies 06:37 - Neuromuscular and Musculoskeletal 10:33 - Renal Disease Catalysts 22:26 - China's New Orphan Rules To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    31 min
  2. Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

    27 ENE

    Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

    New rules in China will accelerate the country’s cell and gene therapy sector by reshaping how investigator-initiated trials are conducted and commercialized. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the new framework and why it will create a powerful incentive for deploying new gene and cell therapies. Executive Editor Selina Koch discusses which milestones she is watching in neurology in the year ahead, from psychedelics to Alzheimer's disease. Finally, Senior Biopharma Analyst Danielle Golovin discusses a pair of stories from BioCentury’s Emerging Company Profile series: one focused on Yale spinout Bexorg Inc., which is rethinking CNS drug discovery with a whole-human-brain model, and another on Elkedonia S.A.S., a French start-up aiming at ELK1 to reboot neuroplasticity in depression. View full story: https://www.biocentury.com/article/658189 00:00 - Introduction 03:14 - Speeding China's Innovation 10:36 - Neuro Catalysts 22:01 - Newcos To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    30 min
  3. Ep. 346 - 2026 Public Markets Preview

    23 ENE

    Ep. 346 - 2026 Public Markets Preview

    The biotech bull is back, and buysiders believe this market has staying power for the first time in nearly five years. On a special episode of the BioCentury This Week podcast, Director of Biopharma Intelligence Stephen Hansen and colleagues discuss Hansen’s 2026 Public Markets Preview, which found interest rates, policy in Washington and fundamentals finally aligning and a wave of launches and M&A that could keep capital flowing into the sector. View full story: https://www.biocentury.com/article/658154 #BiotechBullMarket #PublicMarkets #BiotechMA #IPOOutlook #FDApolicy 00:00 - Introduction 00:41 - Market Sentiment 07:55 - Biotech's Next Wave 14:47 - Lingering Concerns 23:29 - IPOs 26:47 - M&A To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    31 min
  4. Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN

    21 ENE

    Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN

    Next-generation induced proximity technologies are coming of age after a decade of industry focus on PROTACs. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Senior Biopharma Analyst Danielle Golovin’s four-part analysis of how next-generation targeting chimeras (TACs) are evolving. The analysts assess the $2.2 billion takeout of Rapt Therapeutics by GSK, which gave the pharma an allergy asset that the biotech sourced in China in 2024, and movement in Washington on priority review vouchers, NIH’s budget and the White House’s “most favored nation” drug pricing policy. The analysts also discuss takeaways from their meetings on the sidelines of the J.P. Morgan Healthcare Conference. View full story: https://www.biocentury.com/article/658112 #InducedProximity #TargetingChimeras #BiotechMA #DrugPricingPolicy #JPMHealthcare 00:00 - Introduction  03:17 - JPM Highlights 09:17 - GSK's Acquisition of RAPT 14:46 - Next-Generation Targeting Chimeras 21:41 - MFN and Pediatric PRVs To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    31 min
  5. Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation

    15 ENE

    Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation

    The J.P. Morgan Healthcare Conference kicked off this week with sunny skies over San Francisco and more financial momentum than the biotech industry has seen in years. On a special “on the road” edition of the BioCentury This Week podcast, recorded on the sidelines of the annual JPM conference, special guests joined BioCentury’s analysts to discuss the biotech ecosystems in Asia. The wide-ranging conversation spans dealmaking, including the pricing dynamics of assets in China and RNAi’s prospects of becoming the region’s next hot modality; plus the state of the capital markets, the global implications of “China speed” in the clinic, and what’s changing for start-ups in Japan. Joining BioCentury were Panacea Venture’s James Huang, MayTech Global Investments’ Ingrid Yin, DLA Piper’s Ting Xiao and CBRE’s Matt Gardner. The podcast was recorded at the 12th East-West Healthcare Reception, hosted by BioCentury, MayTech Global and Panacea. View full story: https://www.biocentury.com/article/658081 #JPMHealthcare #AsiaBiotech #ChinaBiotech #RNAiTherapeutics #BiotechCapitalMarkets 00:00 - Introduction 02:02 - Split Screen 2026  05:57 - China's Rapid Progress 08:01 - AI and Biotech 16:58 - Deal Prices 22:56 - Public Markets 28:47 - Innovation Across Asia To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    43 min
  6. Ep. 343 - JPM Deals, Policy Outlook, Approval Trends

    13 ENE

    Ep. 343 - JPM Deals, Policy Outlook, Approval Trends

    Riding the tailwind of a strong 2H25, the days leading up to biotech’s annual kickoff meeting in San Francisco delivered billions in capital raised and more than two dozen deals announced. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss two of the largest deals announced at the start of the J.P. Morgan Healthcare Conference, a partnership for a bispecific between AbbVie and RemeGen and the launch of “NewCo” AirNexus Therapeutics by Haisco Pharmaceutical and a syndicate led by Frazier Life Sciences. The analysts also discuss Washington Editor Steve Usdin’s policy outlook for the year ahead, and Executive Director of Biopharma Intelligence Lauren Martz’s analysis of trends in FDA’s 2025 approvals. View full story: https://www.biocentury.com/article/658052 #JPMHealthcare #BiotechFinancing #BiopharmaPartnerships #FDAApprovals #BiotechPolicy 00:00 - Introduction 01:55 - JPM Deals 11:49 - Policy Outlook 19:30 - Trends in Drug Approvals To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    25 min
  7. Ep. 342 - 2026 Biotech Kickoff

    6 ENE

    Ep. 342 - 2026 Biotech Kickoff

    The New Year begins with biotech running along parallel storylines. There’s cause for optimism as the industry’s financing gears have begun to churn again and innovation remains as strong as it has ever been, while there's cause for concern as the world’s most stable, progressive, science-based regulatory system has become unpredictable amid new leadership at HHS, FDA, and NIH. On the first episode of the BioCentury This Week podcast’s seventh year, BioCentury’s analysts assess the state of play for biotech in the U.S., Europe, and Asia. The discussion ranges from recent changes at NIH to what’s next for rare pediatric disease priority review vouchers, and from Europe’s opportunity as FDA enters uncertain terrain to Japan’s evolving biotech landscape. Early bird rates for BioCentury and BayHelix’s fifth East-West Biopharma Summit end Friday. Act now to join investors, dealmakers and innovators in Seoul this March to source innovation from Asia, or accelerate your own pipeline by finding the right Asia partner. View full story: https://www.biocentury.com/article/657978 #BiotechOutlook #FDAUncertainty #GlobalBiotech #RarePediatricDiseasePRV #NIHLeadership 00:00 - Introduction 01:46 - 2026 Outlook 03:56 - Policy Landscape 11:48 - Priority Review Vouchers 15:03 - Global Perspectives 16:57 - Spotlight on Japan 21:55 - European Biotech Opportunities To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    26 min
  8. Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI

    30/12/2025

    Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI

    This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, and new leadership at FDA shuffled the regulatory deck. On the latest BioCentury This Week podcast, BioCentury’s analysts make their picks for the biggest biopharma readouts, deals and regulatory and policy moves of 2025 and what they are forecasting for the year ahead. The analysts also recap biotech highlights of the past two weeks, including the $4.8 billion takeout of Amicus Therapeutics by BioMarin Pharmaceutical. View full story: https://www.biocentury.com/article/657933 #BiotechOutlook2026 #BiopharmaTrends #BiotechMA #FDALeadership #ChinaBiotech 00:00 - Introduction  02:31 - BioMarin's $4.8B Amicus Deal 06:07 - Year-end Biotech Highlights 16:37 - Analyst Picks and Predictions 30:01 - Policy and Regulatory Landscape To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    38 min
Ver todo (358)

Acerca de

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Información

  • Canal
    BioCentury Podcasts
  • Creador
    BioCentury
  • Años de actividad
    2020 - 2026
  • Episodios
    358
  • Clasificación
    Apto
  • Copyright
    © 2026 BioCentury Inc. All Rights Reserved.
  • Mostrar sitio web
    BioCentury This Week

Más de BioCentury Podcasts

También te podría interesar